Eli Lilly and Company $LLY Stock Holdings Decreased by Palacios Wealth Management LLC

Key Points

• Palacios Wealth Management LLC drastically reduced its stake in Eli Lilly and Company by 93.5% during the second quarter, selling over 10,000 shares and leaving it with only 700 shares valued at approximately $546,000.
• Analyst ratings for Eli Lilly are mixed; Daiwa Capital Markets downgraded the stock from "outperform" to "neutral," while DZ Bank upgraded it to "strong-buy" with a forecast price range from $700 to $1,135.
• Insider buying activity has increased, with Director Gabrielle Sulzberger purchasing 117 shares at an average price of $641.18, reflecting confidence in the company's future performance.

Palacios Wealth Management LLC decreased its holdings in Eli Lilly and Company (NYSE:LLY - Free Report) by 93.5% in the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 700 shares of the company's stock after selling 10,026 shares during the period. Palacios Wealth Management LLC's holdings in Eli Lilly and Company were worth $546,000 at the end of the most recent quarter.

Several other institutional investors have also added to or reduced their stakes in the company. WestEnd Advisors LLC lifted its stake in shares of Eli Lilly and Company by 210.0% during the first quarter. WestEnd Advisors LLC now owns 31 shares of the company's stock worth $26,000 after buying an additional 21 shares during the period. Wealth Preservation Advisors LLC acquired a new position in shares of Eli Lilly and Company during the 1st quarter worth about $27,000. Citizens National Bank Trust Department raised its position in shares of Eli Lilly and Company by 180.0% during the 1st quarter. Citizens National Bank Trust Department now owns 42 shares of the company's stock worth $35,000 after purchasing an additional 27 shares during the last quarter. Financial Gravity Asset Management Inc. purchased a new stake in Eli Lilly and Company during the 1st quarter valued at about $40,000. Finally, Mascagni Wealth Management Inc. purchased a new stake in Eli Lilly and Company during the 4th quarter valued at about $43,000. Institutional investors own 82.53% of the company's stock.

Insider Buying and Selling

In other Eli Lilly and Company news, CEO David A. Ricks acquired 1,632 shares of the company's stock in a transaction dated Tuesday, August 12th. The stock was purchased at an average price of $644.77 per share, with a total value of $1,052,264.64. Following the completion of the purchase, the chief executive officer directly owned 546,601 shares in the company, valued at approximately $352,431,926.77. The trade was a 0.30% increase in their position. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director Gabrielle Sulzberger purchased 117 shares of Eli Lilly and Company stock in a transaction dated Tuesday, August 12th. The stock was acquired at an average price of $641.18 per share, for a total transaction of $75,018.06. Following the completion of the acquisition, the director owned 2,703 shares of the company's stock, valued at approximately $1,733,109.54. This trade represents a 4.52% increase in their position. The disclosure for this purchase can be found here. Insiders have purchased a total of 4,514 shares of company stock valued at $2,894,841 over the last ninety days. 0.14% of the stock is owned by insiders.

Eli Lilly and Company Price Performance

Shares of LLY stock traded up $3.33 on Monday, reaching $755.32. The company had a trading volume of 2,524,436 shares, compared to its average volume of 3,388,311. The business's 50-day moving average is $737.49 and its 200 day moving average is $769.01. The company has a quick ratio of 1.00, a current ratio of 1.28 and a debt-to-equity ratio of 1.86. The stock has a market capitalization of $714.88 billion, a PE ratio of 49.37, a price-to-earnings-growth ratio of 1.05 and a beta of 0.47. Eli Lilly and Company has a one year low of $623.78 and a one year high of $939.30.

Eli Lilly and Company (NYSE:LLY - Get Free Report) last announced its quarterly earnings results on Thursday, August 7th. The company reported $6.31 earnings per share (EPS) for the quarter, topping the consensus estimate of $5.59 by $0.72. The business had revenue of $15.56 billion during the quarter, compared to the consensus estimate of $14.40 billion. Eli Lilly and Company had a return on equity of 92.72% and a net margin of 25.91%.Eli Lilly and Company's revenue was up 37.6% compared to the same quarter last year. During the same quarter in the prior year, the company posted $3.92 earnings per share. Eli Lilly and Company has set its FY 2025 guidance at 21.750-23.000 EPS. Equities research analysts forecast that Eli Lilly and Company will post 23.48 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

Several brokerages have commented on LLY. JPMorgan Chase & Co. decreased their price target on shares of Eli Lilly and Company from $1,100.00 to $1,050.00 and set an "overweight" rating for the company in a research report on Tuesday, September 16th. Berenberg Bank restated a "hold" rating and issued a $830.00 price objective (down from $970.00) on shares of Eli Lilly and Company in a research note on Wednesday, September 17th. Morgan Stanley restated an "overweight" rating and issued a $1,135.00 price objective (up from $1,133.00) on shares of Eli Lilly and Company in a research note on Thursday, July 10th. Cantor Fitzgerald lowered their target price on shares of Eli Lilly and Company from $975.00 to $825.00 and set an "overweight" rating on the stock in a report on Wednesday, August 13th. Finally, DZ Bank raised shares of Eli Lilly and Company from a "hold" rating to a "strong-buy" rating in a report on Thursday, August 14th. One research analyst has rated the stock with a Strong Buy rating, fourteen have assigned a Buy rating and nine have given a Hold rating to the company's stock. According to MarketBeat, Eli Lilly and Company currently has a consensus rating of "Moderate Buy" and an average price target of $939.61.

Eli Lilly and Company Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.